128 related articles for article (PubMed ID: 35913013)
1. Predictive value of KRAS/NRAS, IL-4 VNTR and HPV alterations in metastases of colorectal cancer.
Ozen F; Yegin Z; Avsar C; Zenginkinet T; Koc H; Ulasoglu C
Bratisl Lek Listy; 2022; 123(10):758-768. PubMed ID: 35913013
[TBL] [Abstract][Full Text] [Related]
2. Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.
Mahdi Y; Khmou M; Souadka A; Agouri HE; Ech-Charif S; Mounjid C; Khannoussi BE
BMC Gastroenterol; 2023 Jun; 23(1):193. PubMed ID: 37277698
[TBL] [Abstract][Full Text] [Related]
3. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer.
Ounissi D; Weslati M; Boughriba R; Hazgui M; Bouraoui S
Turk J Med Sci; 2021 Feb; 51(1):148-158. PubMed ID: 32892548
[TBL] [Abstract][Full Text] [Related]
7. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
8. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
[TBL] [Abstract][Full Text] [Related]
9. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
10. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study.
Sanchez-Ibarra HE; Jiang X; Gallegos-Gonzalez EY; Cavazos-González AC; Chen Y; Morcos F; Barrera-Saldaña HA
PLoS One; 2020; 15(7):e0235490. PubMed ID: 32628708
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
12. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.
Negru S; Papadopoulou E; Apessos A; Stanculeanu DL; Ciuleanu E; Volovat C; Croitoru A; Kakolyris S; Aravantinos G; Ziras N; Athanasiadis E; Touroutoglou N; Pavlidis N; Kalofonos HP; Nasioulas G
BMJ Open; 2014 May; 4(5):e004652. PubMed ID: 24859998
[TBL] [Abstract][Full Text] [Related]
13. Association between clinicopathological characteristics and RAS mutation in colorectal cancer.
Rimbert J; Tachon G; Junca A; Villalva C; Karayan-Tapon L; Tougeron D
Mod Pathol; 2018 Mar; 31(3):517-526. PubMed ID: 29052598
[TBL] [Abstract][Full Text] [Related]
14. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer.
Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W
Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000
[TBL] [Abstract][Full Text] [Related]
17. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
[TBL] [Abstract][Full Text] [Related]
18. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
19. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
20. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M
PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
